Probiotec Ltd
ASX:PBP
Net Margin
Probiotec Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Probiotec Ltd
ASX:PBP
|
242.3m AUD |
4%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.9B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.3B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
185.9B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
161.1B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
198.9B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
136.3B USD |
13%
|
Probiotec Ltd
Glance View
Probiotec Ltd. engages in manufacture, market and distribution of over-the-counter pharmaceuticals, complementary medicines and specialty ingredients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-11-14. The firm owns approximately six manufacturing facilities in Australia and distributes its products both domestically and internationally. The Company’s products are manufactured on behalf of a range of clients, including international companies. The company also owns Multipack-LJM business, a contract packer, providing packing services for a range of pharmaceutical, consumer healthcare, cosmetics and food, and beverage companies. The firm subsidiaries include Probiotec Pharmaceuticals Pty Ltd, Probiotec Pharma Pty Ltd, Biotech Pharmaceuticals Australia Pty Ltd, Biotech Pharmaceuticals Pty Ltd, Probiotec (NSW) Pty Ltd, Australian Dairy Proteins Pty Ltd, Milton Pharmaceuticals Pty Ltd and Willie Labs Generics Pty Ltd.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Probiotec Ltd's most recent financial statements, the company has Net Margin of 3.9%.
You don't have any saved screeners yet